ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
ProMIS Neurosciences Inc. received an updated ownership report showing that Great Point Partners, LLC, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl beneficially own 409,648 common shares, representing 9.99% of the outstanding class.
The filing explains that this stake includes 238,894 common shares issuable upon exercise of various warrants, which are subject to a 9.99% Beneficial Ownership Cap that limits how many shares can be exercised. The report details warrants held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd. and notes that Great Point, Dr. Jay and Ms. Nordahl may be deemed beneficial owners through their roles, while they disclaim beneficial ownership beyond their pecuniary interests. The reporting group certifies the securities are not held to change or influence control of ProMIS.
ProMIS Neurosciences Inc. disclosed that investment entities affiliated with Trails Edge Capital Partners and Ortav Yehudai have filed a Schedule 13G reporting a 9.9% beneficial stake in its common shares as of February 3, 2026.
The filing shows beneficial ownership of 933,477 shares, consisting of 557,103 common shares and 376,374 shares underlying warrants, held through Trails Edge Biotechnology Master Fund. An additional 180,729 warrant shares are excluded due to a 9.99% ownership cap. Ownership percentages are based on 8,967,740 ProMIS common shares outstanding. The filers certify the holdings are not for changing or influencing control.
ProMIS Neurosciences Inc. received a Schedule 13G filing showing that Deep Track Capital and related entities beneficially own 902,561 common shares, representing 9.99% of the company’s common stock as of February 6, 2026.
The filing explains that this percentage is calculated using 9,034,646 common shares, combining 2,152,444 shares outstanding as of November 12, 2025, 6,815,296 shares issued on January 30, 2026, and 66,906 shares that could be converted up to a 9.99% maximum ownership cap.
The beneficial ownership includes 835,655 warrants that are exercisable into common shares but are subject to a 9.99% “Maximum Percentage” limitation, so exercises cannot push Deep Track’s collective holdings above that threshold.
ProMIS Neurosciences director and Chief Scientific Officer Neil Cashman reported an indirect purchase of 4,122 common shares at $12.13 per share through Research Capital Corporation, along with warrants to buy 4,122 additional common shares. These securities were acquired on February 3, 2026 under a Securities Purchase Agreement with selected investors.
The warrants to purchase common shares have an exercise price of $14.40 per share and are exercisable immediately. They will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from single ascending dose cohorts of PMN310. The filing also notes that common share figures reflect a one-for-twenty-five reverse split completed on November 28, 2025.
ProMIS Neurosciences Chief Development Officer Johanne Kaplan acquired equity on February 3, 2026. Kaplan bought 2,060 common shares at $12.13 per share and received warrants to purchase 2,060 additional common shares, also priced at $12.13 per common share and warrant under a Securities Purchase Agreement with selected investors.
After the transaction, Kaplan beneficially owned 2,312 common shares directly. The warrants have an exercise price of $14.40 per common share and become exercisable on February 3, 2026. They will expire on the earlier of February 3, 2031 or within 60 days after public announcement of topline data from PMN310 single ascending dose cohorts.
ProMIS Neurosciences Inc. insider transaction: Chief Executive Officer and director Neil K. Warma acquired 6,183 common shares of ProMIS Neurosciences Inc. on February 3, 2026 at a price of $12.13 per share. He also received warrants to purchase 6,183 common shares at an exercise price of $14.40 per share.
The warrants become exercisable on February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from PMN310 single ascending dose cohorts.
ProMIS Neurosciences principal accounting officer Max A. Milbury reported purchasing additional equity in the company. On February 3, 2026, he acquired 6,595 common shares of ProMIS Neurosciences Inc. at a purchase price of $12.13 per share under a Securities Purchase Agreement with selected investors.
He also received common share purchase warrants to buy 6,595 additional common shares. These warrants are exercisable starting February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from cohorts treated with single ascending doses of PMN310. Following the transaction, he beneficially owned 8,409 common shares and 6,595 warrants, all held directly.
ProMIS Neurosciences director Patrick D. Kirwin reported buying additional shares and warrants in the company. On February 3, 2026, he acquired 3,050 common shares and warrants to purchase 3,050 common shares under a Securities Purchase Agreement at $12.13 per share and warrant.
Following the transaction, he directly holds 5,135 common shares and warrants for 3,050 common shares with a $14.4 exercise price. He also indirectly beneficially owns 1,653 common shares through Patrick D. Kirwin Professional Corp and 305 common shares through his spouse. The filing notes a one-for-twenty-five reverse split completed on November 28, 2025, and states the warrants expire on the earlier of February 3, 2031 or within 60 days after topline PMN310 single ascending dose data is publicly announced.
ProMIS Neurosciences Inc. large shareholder group led by Fan Yu filed an amended Schedule 13D showing updated ownership after a recent equity financing. The reporting persons collectively report beneficial ownership of 1,644,397 common shares, representing 17.0% of ProMIS’s outstanding common shares.
The filing reflects the closing of an Offering on February 3, 2026, under a Securities Purchase Agreement. Ally Bridge MedAlpha Master Fund L.P. bought 164,881 common shares and warrants for 164,881 shares for $2,000,006.53. ABG V-SIV IX Limited bought 329,760 shares and matching warrants for $3,999,988.80, and ABG V-SIV X Limited bought 206,100 shares and matching warrants for $2,499,993.
The ownership percentages are based on 8,967,693 common shares outstanding immediately after the Offering, and include both currently held shares and shares issuable upon warrant exercise subject to stated limitations. The disclosure also notes a 1-for-25 reverse stock split completed on November 28, 2025.
ProMIS Neurosciences Inc. saw a group of Ally Bridge–affiliated investors report a new insider purchase. On February 3, 2026, they acquired 700,741 Common Shares of ProMIS at $12.13 per share, bringing their indirectly beneficially owned Common Shares to 943,090.
The investors also acquired Warrants to purchase 700,741 Common Shares, with a stated exercise price of $14.40. These Warrants are exercisable immediately and will expire on the earlier of within 60 days after a defined PMN310 topline-data Milestone Event or February 3, 2031.
The Common Shares and Warrants are held across Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited, with ABG Management Ltd., Ally Bridge Group (NY) LLC, Fan Yu and director Alex Slanix Paul reported as sharing beneficial ownership through various control relationships.